FDA-approved products are being moved to Schedule III following a rescheduling order finalized by the DOJ and DEA, involving Curaleaf.
1 report, 1 independent
Updated Jun 17
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA-approved products are being moved to Schedule III following a rescheduling order finalized by the DOJ and DEA, involving Curaleaf.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- A DOJ/DEA order moves FDA-approved cannabis products, which subsequently affects Nasdaq's new listing pathway.Sub-event
- Curaleaf prepares for US exchange uplisting as DEA rescheduling deadlines drive ETF performance and regulatory reclassification.Sub-event
DOJ and DEA finalize rescheduling order, moving FDA-approved products to Schedule III.1 source